Stock Track | Ginkgo Bioworks Plummets 5.32% as Baby Switching Allegations Surface at Hospital

Stock Track
2024/12/13

Ginkgo Bioworks Holdings Inc. (DNA), a leading synthetic biology company, witnessed a 5.32% plummet in its stock price on Friday, amidst allegations of a potential baby switching incident at the RS Islam Cempaka Putih hospital.

The stock's decline followed reports of a father, identified as MR, suspecting that the baby he received after his wife's delivery was not their biological child. MR claimed discrepancies in the physical appearance and measurements of the baby compared to the birth certificate details.

While the hospital has denied any baby switching incident, the allegations raise concerns over potential DNA mixups and mishandling of sensitive biological samples. As a biotechnology firm specializing in DNA engineering and synthetic biology, such incidents could potentially damage Ginkgo Bioworks' reputation and investor confidence in the company's operations and practices.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10